4.5m people received other plasma-based products to help treat sepsis, cirrhosis, hypoalbuminemia and a range of other conditions 1.3m pregnant women treated for rhesus incompatibility 7.8k people with functional protein disorders (including hereditary angioedema and alpha-1 antitrypsin deficiency) 165k people with autoimmune diseases and immune deficiencies 6.6k people with haemophilia A & B Logan. Lives with Haemophilia B. Treatments for Serious and Rare Diseases We deliver plasma-derived and recombinant therapies for people living with serious and rare conditions including: • Hereditary bleeding disorders such as haemophilia, fibrinogen deficiency and von Willebrand disease • Immune deficiencies and autoimmune conditions such as chronic inflammatory demyelinating polyneuropathy, Guillain‑Barré syndrome, Kawasaki disease, rhesus incompatibility, primary immunodeficiency and secondary immunodeficiency • Other genetic conditions such as hereditary angioedema (HAE) and alpha‑1 antitrypsin deficiency (AATD) In FY2025, our medicines treated: 5 Limited Our Impact 2025 About CSL From our CEO Healthier Communities Science and Medicine Legacy Lifesaving Medicines
RkJQdWJsaXNoZXIy MjE2NDg3